Craft
  • Home
  •  / WuXi Biologics
WuXi Biologics

WuXi Biologics

Pre-clinical Projects

287

H1, 2022

Revenue

¥10.3 B

FY, 2021

Market Capitalization

$215.2 B

2022-11-11

WuXi Biologics Summary

Company summary

Overview
WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. It helps organizations discover, develop, and manufacture biologics from concept to commercial manufacturing. The company also delivers cell line development and analytical protein characterization services.
Type
Public
Status
Active
Founded
2010
HQ
Wuxi, CN | view all locations
Website
https://www.wuxibiologics.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Chris Chen

    Chris Chen, Chief Executive Officer of WuXi Biologics, Chairman of WuXi Vaccines, Chairman of WuXi XDC

    • Weichang Zhou

      Weichang Zhou, Chief Technology Officer, Executive Vice President

    • Jijie Gu

      Jijie Gu, Chief Scientific Officer, Executive Vice President

    • Ming Tu

      Ming Tu, Chief Financial Officer, Executive Vice President

      Operating MetricsView all

      Pre-clinical Projects

      287
      35.4%

      H1, 2022

      Late-phase Projects

      43
      34.4%

      H1, 2022

      Phase I Projects

      144
      24.1%

      H1, 2022

      LocationsView all

      7 locations detected

      • Wuxi, Jiangsu Sheng HQ

        China

        108, Meiliang Road, Mashan

      • Cranbury, NJ

        United States

        7 Clarke Dr

      • King of Prussia, PA

        United States

        411 Swedeland Rd

      • George Town, George Town

        Cayman Islands

        PO Box 309, Ugland House

      • Wuppertal, NRW

        Germany

      • Hong Kong, Hong Kong Island

        Hong Kong

        level 54, hopewell centre 183 queen’s Road

      and 1 others

      WuXi Biologics Financials

      Summary financials

      Revenue (H1, 2022)
      ¥7.2B
      Gross profit (H1, 2022)
      ¥4.0B
      Net income (H1, 2022)
      ¥2.6B
      Cash (H1, 2022)
      ¥8.5B
      EBIT (H1, 2022)
      ¥2.6B
      Enterprise value
      $211.2B

      Footer menu